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A B S T R A C T
One of the main functions of mitochondria is production of ATP for cellular energy needs, however, it becomes
more recognized that mitochondria are involved in differentiation and activation processes of immune cells.
Upon activation, immune cells have a high need for energy. Immune cells have different strategies to generate
this energy. In pro-inflammatory cells, such as activated monocytes and activated T and B cells, the energy is
generated by increasing glycolysis, while in regulatory cells, such as regulatory T cells or M2 macrophages,
energy is generated by increasing mitochondrial function and beta-oxidation.
Except for being important for energy supply during activation, mitochondria also induce immune responses.
During an infection, they release mitochondrial danger associated molecules (DAMPs) that resemble structures
of bacterial derived pathogen associated molecular patterns (PAMPs). Such mitochondrial DAMPS are for in-
stance mitochondrial DNA with hypomethylated CpG motifs or a specific lipid that is only present in prokaryotic
bacteria and mitochondria, i.e. cardiolipin. Via release of such DAMPs, mitochondria guide the immune response
towards an inflammatory response against pathogens. This is an important mechanism in early detection of an
infection and in stimulating and sustaining immune responses to fight infections. However, mitochondrial
DAMPs may also have a negative impact. If mitochondrial DAMPs are released by damaged cells, without the
presence of an infection, such as after a trauma, mitochondrial DAMPs may induce an undesired inflammatory
response, resulting in tissue damage and organ dysfunction. Thus, immune cells have developed mechanisms to
prevent such undesired immune activation by mitochondrial components.
In the present narrative review, we will describe the current view of mitochondria in regulation of immune
responses. We will also discuss the current knowledge on disturbed mitochondrial function in immune cells in
various immunological diseases.
1. Introduction
The mitochondrion is a double membrane organelle present in al-
most all cells. Evolutionary, it is suggested that mitochondria are de-
rived from bacteria merging with proto-eukaryotic cells [1]. A major
function of mitochondria is the supply of ATP for cellular energy needs
[1]. However, it is becoming more and more apparent that mitochon-
dria have various other important roles in the cells, such as for instance
regulating apoptosis [2] and also regulating immune responses which
protect the body against infections and cancer [3]. Mitochondria are
able to affect immune cell function in various ways, such as for instance
by production of reactive oxygen species (ROS), which are generated by
mitochondria via the electron transport chain [4]. ROS function as
second messengers in various signaling pathways in immune cells, for
instance in the Ca2+-NFAT signaling pathway, which is critical in T cell
activation [5]. ROS can also damage bacterial pathogens, but if pro-
duced excessively it can also undesirably damage the producing cell or
neighboring cells. The role of other mitochondrial products, such as
mitochondrial DNA and proteins, in triggering and maintaining im-
mune responses has also been recently recognized [6]. Not only via
mitochondrial components but also via the generation of energy mi-
tochondria are essential for inducing and regulating immune responses
[7]. As recent discoveries have given timely and new insights in how
mitochondrial processes might contribute to forming pro- or regulatory
immune responses, we have decided to write this narrative review. The
review will focus on the various functional roles of mitochondria in
immune cells and in activating immune responses and will shortly
discuss the function of mitochondria in immune cells in some im-
munological diseases.
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One of the main functions of mitochondria is to accomplish oxida-
tive phosphorylation and produce ATP [8]. Oxidative phosphorylation
is a highly efficient mechanism for ATP production and uses an electron
transfer chain driven by oxidation of various substrates [9]. The
movement of electrons down the mitochondrial electron transport
chain is associated with the transport of protons across the mitochon-
drial membrane. This creates an electrochemical gradient (mitochon-
drial membrane potential), which is used to phosphorylate ADP to ATP
[10]. NADH2 and FADH2 are used by the electron transport chain to
generate electrons. NADH and FADH are refueled by the tricarboxylic
acid (TCA) cycle. The TCA cycle is fed by various substrates, such as
fatty acids and pyruvate, which are converted to acetyl-CoA by beta-
oxidation and pyruvate dehydrogenase, respectively, before entering
the TCA cycle [11]. Pyruvate is produced via glycolysis, in which glu-
cose is converted to pyruvate. Pyruvate can be used by the TCA, but can
also be reduced to lactate (aerobic glycolysis), which results in quick,
but relatively inefficient ATP production, and production of lactate
[12]. Glycolysis also fuels the Pentose Phosphate Pathway, which effi-
ciently synthesizes nucleotides and NADPH [7]. Amino acids, such as
glutamine can also be used by the TCA, after conversion through glu-
taminolysis to alpha-ketoglutarate [7]. Depending on the metabolic
state of the cell, the TCA cycle fuels the electron transport chain or TCA
intermediates are transported out of the mitochondria into the cytosol,
where they may be used for building fatty acids or nucleotides or
function as important signaling molecules. ROS are such signaling
molecules [13] and are produced at various sites in the mitochondria
[4]. (See “resting immune cells” in Fig. 1). Since excessive ROS pro-
duction can also damage cells, important ROS scavenging systems are
present in the cells, such as superoxide dismutase (SOD) or catalase [4].
Changes in either mitochondrial activity, such as changes in the mi-
tochondrial membrane potential, or changes in the ROS scavenging
system determine mitochondrial ROS production [4].
Differences in mitochondrial function are linked to dynamics in
mitochondrial morphology [14]. Mitochondrial morphology is regu-
lated by so-called fusion and fission events, which in their turn are
regulated independently by a complex protein machinery. The fusion of
the outer membrane between 2 adjacent mitochondria is mediated by
mitofusin 1 and 2 [15]. After outer membrane fusion, the dynamin-like
GRPase optic atrophy (OPA) mediates fusion of the inner membrane
[15]. The other protein important for inner membrane fusion is Car-
diolipin [16]. Mitochondrial fission of the outer membrane is depen-
dent on dynamin-related protein 1 [17]. It remains unclear whether
fission of the outer membrane is sufficient to drive fission of the inner
membrane but two inner membrane proteins, i.e. mitochondrial protein
18 (MTP18) and short Optic Atrophy −1 (OPA1), are probably im-
portant [18]. Fusion of mitochondria is important for maintenance of
mitochondrial DNA integrity and for cellular respiration [19]. Fission of
the mitochondria is important to allow inheritance of mitochondria by
daughter cells during cell division [20]. Fission is also important when
mitochondria are damaged and deleted, since the segregation of da-
maged mitochondria facilitates their removal by mitophagy [21]. Mi-
tochondrial fission and fusion processes are responsible for dynamics in
mitochondrial morphology, which can vary significantly between tis-
sues and cells. For example in activated T cells the fission and fusion
processes result in more fragmented mitochondria while in neurons it
induces formation of more tubular mitochondria [22,23]. Notably,
however, fission and fusion processes occur also in response to various
extra- or intracellular changes, such as changes in nutrient supply or in
energy or redox status, but also during cell differentiation in a cell-type
dependent manner. This is for instance seen when comparing effector T
cells and memory T cells. Active effector T cells have more fragmented
mitochondria, while long-lived, less active memory T cells have a more
fused mitochondrial network [22]. Moreover, various disease are as-
sociated with fragmented mitochondria [24] which might be an
important indicator and target for management of disease.
Mitochondria are not only important as energy suppliers and for
functioning of immune cells, they also have a role in antiviral signaling.
Mitochondria control signaling pathways to restrain viral infections
[25]. A major role is played by the mitochondrial antiviral signaling
(MAVS) protein, which is localized in the mitochondrial membrane
[26]. Viral RNA is sensed by the retinoic acid-inducible gene I (RIG-I)-
like receptors (RLRs), which are present in the cytosol [27]. Following
RNA binding, RIG-I and melano differentiation associated gene 5, two
members of this family, oligomerize and activate the downstream
MAVS [28]. MAVS induces via various pathways the expression of type
I and II interferons, important for clearing of the virus, and the acti-
vation of Nuclear Factor-kB (NF-kB), important for activating the innate
and adaptive immunity [29].
3. Mitochondrial function in immune cells
Upon activation of immune cells, immune cell function alters, since
for instance large amounts of cytokines and chemokines need to be
produced or immune cells need to migrate to inflamed tissues. Such
processes demand large amounts of energy and adaptations of the en-
ergy producing mechanisms. Immediate fuel of cellular energy can be
induced by increasing glucose uptake and upregulation of glycolysis,
which is used by for instance monocytes [30] and M1 macrophages
[31]. Often these immune cells do not use all pyruvate for the TCA cycle
and mitochondrial oxidation, but use it for aerobic glycolysis, produ-
cing ATP, albeit in low amounts [32]. Mitochondrial oxidation can also
be upregulated upon activation of immune cells, but this requires mi-
tochondrial biogenesis, which takes longer [33]. Glutamine is also often
used as an energy source for activated immune cells [34]. These
changes in metabolism in activated immune cells will be described in
more detail for various immune cells below.
The mechanistic target of rapamycin (mTOR) is an evolutionary
conserved signaling pathway that senses and integrates various stimuli,
such as pathogen associated molecular patterns (PAMPs), growth fac-
tors and cytokines, to coordinate metabolic adaptations and regulate
growth,proliferation and function of immune cells [35]. The ser/thr
kinase mTOR exists in two mTOR complexes: mTOR complex 1
(mTORC1) and mTOR complex 2 (mTOR C2) [36,37]. Both can be
activated by various immunological stimuli, such as growth factors,
Toll-like receptor ligands or LPS, but also by intracellular stimuli, such
as amino acids [38]. Such stimuli result in activation of phosphoino-
sitide 3-kinase (PI3K), which directly, mTORC2, or via Akt (Protein
Kinase B), mTORC1, activates mTOR [39]. The central function of
mTORC1 is to induce cellular growth and proliferation, while mTORC2
is involved in Th polarization and actin cytoskeleton dynamics, which
are important for cellular movement [39]. MTORC1 promotes amongst
others translation of metabolic enzymes necessary for cell proliferation
and the synthesis of transcription factors HIF1α and Myc, which are
important for programming the metabolism in activated immune cells,
and positively regulate glycolysis [40]. MTORC2 can also enhance
glycolysis [41].
3.1. Mitochondrial function in innate immune cells
The immune system is important in the body's defense against in-
fection and cancer. The immune system consists of 2 arms: the adaptive
immune system and the innate immune system [3]. The innate immune
system is the first line of defense against infections [3]. Cells of the
innate immune response are monocytes, macrophages/dendritic cells,
granulocytes (neutrophils, eosinophils and basophils), but also innate
lymphocytic cells (ILCs), including natural killer (NK) cells [3]. Their
main functions are cytokine production, phagocytosis, lysis of infected
cells, or presenting antigens to T cells [3]. Innate immune cells re-
cognize structures specific for microbes such as so called microbe or
Pathogen associated molecular patterns (PAMPs), which are microbial
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molecules, such as LPS or flagellin [42]. They also recognize eu-
karyote's own cell derived molecules, such as damage associated mo-
lecular patterns (DAMPS), amongst which is mitochondrial DNA. For
recognition of PAMPs and DAMPs, the innate immune cells have spe-
cific receptors, Pattern Recognition Receptors (PRRs), the most well-
known being Toll-like Receptors (TLR) [42].
3.1.1. Monocytes
Blood monocytes arise from precursors in the bone marrow and
about 5–10% of all circulating blood leukocytes is monocyte [43].They
circulate in the blood for 24–48 h., after which they migrate into tissues
to become macrophages or dendritic cells [43]. They are important for
regulating immune responses, inflammation and tissue repair. They
produce cytokines, are phagocytotic and present antigens to cells of the
adaptive immune system [43]. Three subsets of monocytes are cur-
rently distinguished: classical monocytes (CD14++/CD16low),
intermediate monocytes (CD14++/CD16+) and non-classical mono-
cytes (CD14low/CD16+) [44]. Classical monocytes (80–90% of all
monocytes) are phagocytes, produce reactive oxygen species and pro-
duces cytokines in response to TLR activation. Non-classical monocytes
(5–10% of all monocytes) are efficient producers of pro-inflammatory
cytokines; they have been shown to be increased in various in-
flammatory conditions [44]. The function of intermediate monocytes is
less clear and it is thought that they may have an intermediate function
between classical and non-classical monocytes [44].
Various studies have focused on mitochondrial function in mono-
cytes but it is unknown whether there are differences in mitochondrial
function between the three subsets of monocytes. Most studies in
monocytes have been done in the total monocyte population, which
consists mainly of classical monocytes. Monocytes, like other immune
cells, upregulate their metabolism after activation to meet the high
energy demands of activation [30]. Common pro-inflammatory
Fig. 1. Mitochondrial metabolism in resting immune cells and in activated monocytes, M1 macrophages, M2 macrophages, Treg cells and memory cells, and in
activated T and B cells.
In pro-inflammatory cells, like activated monocytes, ILCs1, M1 macrophages and activated T and B cells the high demand for energy is fueled by increasing glycolysis.
However, the role of mitochondrial function differs between these pro-inflammatory cells, since little changes in mitochondrial function are observed in LPS activated
monocytes, while a deficient TCA cycle is observed in M1 macrophages and increased mitochondrial function is characteristic for activated T and B cells and
monocytes activated by other stimuli, such as TLR2 ligands. Regulatory cells and long-lived cells (M2 macrophages, Treg cells and memory T cells) mainly rely on
beta-oxidation and increased mitochondrial function.
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monocyte stimuli, such as LPS, induce a glycolytic burst and reduce
oxidative phosphorylation, and upregulate lactate, which is similar to
the Warburg effect seen in cancer cells [30,45,46] (see Fig. 1). This
increased glycolysis increases ROS production in monocytes [45].
However, at sites of inflammation, glucose concentration often de-
creases, after which monocytes shift their metabolism to oxidative
phosphorylation, fueled by fatty acid oxidation. Fatty acids are derived
from the lipid droplets insight the cell [46].
Other stimuli than LPS, can induce oxidative phosphorylation in
monocytes. The upregulation of glycolysis and downregulation of oxi-
dative phosphorylation, as described above, appears to be specific for
LPS engaging the TLR4, since stimulation of monocytes with for in-
stance TLR2 ligands, such as Pam3CysSK4, increased glycolysis but also
increased oxidative phosphorylation [47]. Similarly, stimulation of
human monocytes with the yeast Candida albicans or the live attenuated
Bacillus Clamette-Guerin (BCG) vaccine increased glycolysis but also
oxidative phosphorylation [48,49]. Stimulation of monocytes with
fungal components, like B-glucans, induced glycolysis and decreased
oxidative phosphorylation, like LPS [50]. These data indicate that
metabolic changes in activated monocytes may depend on the stimulus.
Some studies suggest an important role for early oxidative stress and
increased mitochondrial respiratory activity in monocytes in immune
paralysis during sepsis [51]. Sepsis is a serious condition caused by an
inflammatory response triggered by PAMPs, such as LPS, during an
infection [52]. The important role of monocytes in sepsis is well-known
[53]. Monocytes are activated in sepsis followed by subsequent immune
paralysis [53]. A recent study into activation of the monocytic cells
(THP-1 cells) by LPS showed that the immune paralysis is associated
with early oxidative stress and increased mitochondrial respiratory
activity [51]. The authors also demonstrated increased autophagy of
mitochondria (mitophagy) as well as an increased mitochondrial
synthesis and upregulation of antioxidant defenses during immune
paralysis [51]. These data suggest occurrence of mitochondrial dys-
function during immune paralysis and replacement of dysfunctional
mitochondria in order to inhibit oxidative stress and increase mi-
tochondrial respiratory activity [51]. Unfortunately, not many studies
on mitochondrial function in septic patients have been performed. One
study showed increased mitochondrial enzyme activity of the electron
transport system, indicating increased ATP production in septic
monocytes. However, ATP content did not increase, suggesting an in-
creased metabolic demand and thus ATP consumption [54]. A few
studies have looked at mitochondrial function in monocytes in other
conditions. It has been shown that ageing, which is associated with a
low grade inflammatory response, called inflammaging [55], decreased
mitochondrial function in classical monocytes and possibly also in non-
classical monocytes [56], by impairing mitochondrial respiratory ca-
pacity [55]. Both type 2 diabetes and obesity were associated with
decreased monocyte mitochondrial function [57,58].
Activation of monocytes by TLR ligands induces the activation of
mTORC1 and mTORC2, which enhance not only glycolysis [45], but
also the production of chemokines and cytokines [59]. Activation of
mTORC1 increases proinflammatory cytokine production, while in-
hibition of mTORC1 inhibits proinflammatory cytokine production
[60].
Recently, it was shown that not only adaptive immune cells develop
memory, but that also innate immune cells develop memory, called
trained immunity [61]. Trained immunity has been shown for various
innate immune cells, including monocytes, and can be induced by sti-
muli like β-glucan or the Bacillus Calmette-Guérin (BCG) vaccine [61].
Trained memory allows innate immune cells to respond stronger and
more rapidly upon subsequent triggers [61]. The mechanisms inducing
trained immunity have mainly been studied in monocytes in vitro.
Trained immunity seems to result from epigenetic changes, induced by
metabolic pathways [61]. Recently, Arts et al. showed that increased
glycolysis, glutaminolysis and cholesterol synthesis pathways are
needed to induce trained memory in monocytes [62].
3.1.2. Macrophages
Macrophages are tissue resident cells, which are important in de-
tecting, phagocytosing and processing foreign material, such as bacteria
or dead cells [43]. Macrophages play an important role in inflammatory
processes in tissues, but they also have anti-inflammatory or regulatory
properties, with which they are involved in resolution of inflammation
[43]. Like for monocytes, several macrophages subtypes have been
described. Macrophages can be classified into M1 macrophages, which
are microbicidal and pro-inflammatory, or M2 macrophages, which are
anti-inflammatory or immunomodulatory and can induce resolution of
inflammation [43]. M1 macrophages secrete many pro-inflammatory
molecules, such as IL-12, TNF-alpha and nitric oxide (NO) [63]. They
are implicated in the clearance of various types of microbial infections
[63]. M2 macrophages produce molecules that modulate inflammation
and promote tissue repair and are involved in responses to helminth
parasites [63]. These populations, however, may be the extreme ends of
polarization, since various subtypes in between M1 and M2 macro-
phages have been described [63].
Macrophages stimulated with LPS differentiate into M1 macro-
phages, while macrophages stimulated with IL-4 or IL-13 differentiate
into M2 macrophages [64]. It has recently become recognized that not
only LPS or cytokines can mediate differentiation towards macrophage
phenotypes, also the cellular metabolism is very important for de-
termining macrophage phenotype [65]. Similar to monocyte activation
by LPS as described above, stimulation of macrophages with LPS (i.e.
differentiation towards M1 macrophages), increases glucose uptake and
glycolysis [31] (see Fig. 1). This increased glycolysis seems to be the
result of an upregulation of the enzyme ubiquitous 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase (uPFK2), inducing high concentra-
tions of fructose-2,6-bisphosphate, which potentiates glycolysis [31].
This is associated with the production of HIF1α, which induces pro-
inflammatory IL-1β production and upregulation of several enzymes
involved in glycolysis [66]. Not only glycolysis, but also the Pentose
Phosphate Pathway is increased in M1 macrophages. This is the result
of downregulation of the enzyme carbohydrate kinase-like protein
(CARKL) [66], which inhibits this Pentose Phosphate Pathway [67].
The Pentose Phosphate Pathway generates nucleotides and NADPH [7],
the latter is important for mitochondrial ROS production [67]. M1
macrophages also increase glutamine metabolism, which is used as
alpha-ketoglutarate in the TCA cycle after glutaminolysis [66]. This
stimulates succinate accumulation [66]. Succinate stabilizes HIF1α
[66]. M1 macrophages have an impaired TCA cycle, with two deficient
steps [66,68]. The first deficiency results in accumulation of citrate in
the cytosol of the cell [68,69]. This citrate can be used for synthesis of
lipids (prostaglandins), nitric oxide or ROS [70], which are important
for M1 macrophage function. The other break in the TCA cycle leads to
accumulation of succinate [66] (see Fig. 1).
Relatively little is known about the cellular metabolism in M2
macrophages. In contrast to M1 macrophages, which largely depend on
glycolysis due to the upregulation of uPFK2, M2 macrophages do not
upregulate uPFK2, and therefore do not increase glycolysis [31]. M2
macrophages are thought to be dependent on beta-oxidation [71,72].
Beta-oxidation in IL-4 activated macrophages is upregulated by induc-
tion of the nuclear receptors PPAR-y and PPAR-δ [71,73,74]. Exo-
genous lipoproteins are used as a source for fatty acids in M2 macro-
phage, which are taken up by CD36 and broken down to fatty acids in
the lysosome [72]. Enhanced beta-oxidation is associated with an in-
creased TCA, increased respiratory capacity, and thus with an increased
capacity to produce ATP by oxidative phosphorylation. Whether this is
important for M2 macrophage function, such as for production of var-
ious M2 specific regulatory factors or factors associated with tissue
repair, and/or for longevity remains to be established. M2 macrophages
also upregulate consumption of glutamine [68]. In contrast to M1
macrophages, in M2 macrophages, this is mainly used in the hex-
osamine pathway and upregulates N-glycosylation, which is important
for several M2 markers [68].
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Activation of Akt and mTOR in M1 macrophages is important for
inducing HIF1α and therefore inducing glycolysis [50]. It is also im-
portant for the balance of pro- and anti-inflammatory cytokine pro-
duction, as well as for macrophage polarization: inhibition of mTORC1
with rapamycin increased M1 macrophage polarization [75], while in
M2 macrophages, activation of mTORC1 is a negative regulator of in-
duction of M2 macrophages, while mTORC2 is critical for M2 macro-
phage induction [76]. In M1 macrophages, it has been shown that
mTORC1 inhibition increases the production of proinflammatory cy-
tokines, and inhibits the production of the anti-inflammatory IL-10
[60], while on the other hand mTORC1 activation enhanced the pro-
duction of IL-10 and decreased the production of the proinflammatory
cytokines [60]. mTORC1 limits the production of proinflammatory
cytokines by inhibiting the activation of NF-kB [60,76].
Trained immunity can also be observed in macrophages [61]. This is
associated with changes in mTOR activity [50]. After in vitro stimula-
tion of monocytes derived macrophages with β-glucan, macrophages
respond with exaggerated proinflammatory cytokine production fol-
lowing a subsequent stimulus with β-glucan or a TLR agonist [62]). This
trained immunity is associated with the Warburg effect (i.e. increased
glycolysis and reduced oxidative phosphorylation) as well as an in-
creased Pentose Phosphate Pathway and cholesterol metabolism [62].
It is also associated with an increased expression of mTOR, mainly
mTORC1 [62,50], and the downstream targets of mTOR, such as HIF1α
[50]. This latter upregulation results from epigenetic changes at pro-
motors in the mTOR pathway [50].
3.1.3. Innate lymphocytic cells
ILCs are the innate counterpart of T cell subsets. They are lym-
phocyte like cells, since they are derived from the common lymphoid
precursors, but they lack expression of antigen receptors found on T or
B cells, such as CD3 or CD19 [77]. They are primarily tissue resident
cells, and can be found in lymphoid tissue and non-lymphoid tissue
[78]. They play key roles in immune responses to pathogens in all or-
gans, since they can rapidly secrete cytokines, but they are particularly
important at mucosal tissues and play a key role in mucosal immunity
[79]. Three types of ILCs can be distinguished: ILCs1, ILCs2 and ILCs3.
ILCs1 are comprised of NK cells and other ILCs1 cells and are dependent
on the T-box transcription factor Tbet for development and function
and they produce interferon-gamma (IFNγ); ILCs2 are dependent on the
transcription factors GATA binding protein 3 (GATA3) and RAR-related
orphan receptor α (RORα) and produce type 2 cytokines, such as IL5
and IL13; ILCs3 are dependent on the transcription factor RAR-related
orphan receptor gamma T (RORɣT) and produce IL-17 and IL-22 [77].
Mitochondrial function in ILCs has recently been reviewed by Rolot
et al. [80]. Like other immune cells, naïve quiescent ILCs mainly use
glycolysis and oxidative phosphorylation to provide ATP for energy
requirements [81]. Upon activation, different ILCs use different energy
generating strategies. NK cells, as part of the ILC1 group, upregulate
glycolysis to provide for the increased demand for amino acids, lipids
and nucleotides during activation and proliferation [81]. ILCs2 can also
increase glycolysis upon activation, this, however, depends on arginase-
1 activity, which metabolizes L-arginine to polyamines (derived from
ornithine) to fuel glycolysis [82]. ILCs2 can also take up long chain fatty
acid and use fatty acid oxidation for proliferation and function [83].
ILCs3 can increase glycolysis and fatty acid oxidation as well increase
the mitochondrial respiratory function [84].
3.2. Mitochondrial function in adaptive immune cells
The adaptive immune system consists of T lymphocytes and B
lymphocytes. B lymphocytes upon stimulation can develop into plasma
cells, which are antibody producing cells [3]. B lymphocytes are also
professional antigen presenting cells and they can secrete cytokines [3].
T lymphocytes are identified by their T cell receptor. Two T lymphocyte
subsets can be distinguished: CD4+ T helper cells and CD8+ cytotoxic
T cells. Cytotoxic T cells act mainly by killing cells through cell-cell
interaction [3]. T helper cells produce cytokines upon antigen stimu-
lation, thereby coordinating the immune response [3]. T helper cells
can be divided into various subpopulations, based on their effector
function. The main and most studied subpopulations are T helper 1
(Th1), Th2, Th17 and regulatory T cells (Treg). Th1 cells are involved in
cell-mediated immunity and characterized by production of Th1 cyto-
kines, such as IFNɣ. Th2 cells are involved in humoral immunity and
produce Th2 type cytokines, such as interleukin 4 (IL-4). Th17 cells
produce IL-17, and are involved in mucosal immunity and inflamma-
tion. These subsets are called effector T cells [3]. Treg cells are iden-
tified by the expression of the transcription factor Forkhead box P3
(FOXP3). Treg cells can suppress other immune cells, such as other T
cells, but also macrophages and dendritic cells, thereby controlling both
innate and adaptive immune responses [85]. An important feature of
adaptive immunity is their ability to generate long-lived memory cells,
that are able to respond more rapidly upon reinfection [3].
3.2.1. B lymphocytes
Antigen specific B lymphocytes become activated upon en-
countering a cognate antigen and with co-stimulation of T cells. [3].
They then migrate to secondary lymphoid tissues and start proliferating
[86]. They undergo immunoglobulin class switching and differentiate
into plasma cells producing large amounts of antibodies [3,86]. Upon
activation, B lymphocytes upregulate both oxidative phosphorylation
and glycolysis [87] (see Fig. 1). Activated B lymphocytes also have
increased mitochondrial mass as well as increased ROS production
compared to resting cells [88,89]. ROS production in B lymphocytes is
necessary for B cell activation [88]. Upon differentiation to plasma
cells, glycolysis and oxidative phosphorylation is further upregulated
[87], and upon further differentiation into long-lived plasma cells, the
maximal capacity for oxidative phosphorylation is even further in-
creased [90]. This is due to increased glucose uptake and mitochondrial
pyruvate import [90]. Upregulation of glycolysis in activated B lym-
phocytes is induced by phosphoinositide 3 kinase (PI3K) and upregu-
lation of mTOR [91]. It has been shown the mTORC1 is important for B
cell development and survival [92]. Both mTORC1 and mTORC2 have
been shown to be important for antibody class switching [93,94].
3.2.2. Effector T cells
Resting naïve T cells have a low rate of nutrient uptake and rely on
oxidative phosphorylation to generate ATP for their survival. This is
fueled by oxidation of glucose, glutamine and fatty acids [95]. Upon
activation, effector T cells immediately increase glucose uptake and
glycolysis to rapidly produce ATP [95] (see Fig. 1). In contrast to ac-
tivated innate immune cells, in which oxidative phosphorylation is
relatively inhibited and pyruvate is used in aerobic glycolysis and the
Pentose Phosphate Pathway, in effector T cells oxidative phosphoryla-
tion is increased upon activation [96]. This is associated with an in-
crease in mitochondrial mass and mitochondrial DNA levels in the first
hours of activation [96,97]. This increase in oxidative phosphorylation
is indispensable for T cell proliferation upon activation, since blocking
the electron transport chain reduces T cell proliferation [97]. The in-
crease in oxidative phosphorylation in activated T cells is also im-
portant for production of ROS, which is required for intracellular sig-
naling during activation of T cells [98]. Oxidative phosphorylation in
effector T cells is supported by glutamine uptake, which through glu-
taminolysis is converted to alpha-ketoglutarate and used in the TCA
cycle for oxidative phosphorylation [99]. Glutamine uptake seems to be
essential for effector T cells, since restriction of glutamine converts
naïve T cells into Treg cells [100].
Although the above-described mitochondrial metabolism in effector
T cells is general for these cells, within the effector T cells subpopula-
tions, there are differences in mitochondrial metabolism. For instance,
mitochondrial dysfunction in T cells induced by depletion of mi-
tochondrial transcription factor A (TFAM) (one of the mitochondrial
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genes) induces an increased glycolysis and differentiation towards Th1
cells and not towards the other subpopulations [97], suggesting the Th1
cells depend less on mitochondrial respiration than the other subtypes.
The dependence of effector T cells on glycolysis is associated with a
role of mTOR in these cells. Activation of mTOR is important for the
development of Th subsets, such as Th1, Th2 and Th17 [101]. mTORC1
is important for Th1 and Th17 cell differentiation [101]; mTORC2 may
play a role in Th1 cells [102] and in Th2 cell differentiation [102].
3.2.3. Regulatory T cells
The metabolism of Treg cells is different from the metabolism of
effector T cells and unfortunately, less is known about mitochondrial
function in Treg cells. Treg cells use fatty acid oxidation and oxidative
phosphorylation, rather than glycolysis, to induce Treg specific differ-
entiation such as expression of FOXP3 and sustain their im-
munoregulatory function [103–105]. Treg stability is further achieved
by FOXP3 specific suppression of glycolysis and Myc signaling [106],
and enhanced oxidative phosphorylation and NAD+ generation [103]
(See Fig. 1). The fact that Treg cells do not need glycolysis for their
induction is in line with the finding that activation of mTORC1 is not
necessary for Treg induction [40], and both loss of mTORC1 and
mTORC2 induces Treg differentiation in T cells [101]. However,
mTORC1 does play a role in Tregs: activation of mTORC1 induces
proliferation in these cells while inhibiting the suppressive activity
[107]. Indeed, activation of Tregs with TLR ligands promotes glycolysis
and proliferation of Treg cells and inhibits suppressive activity via the
mTOR pathway [108]. This findings are in line with the findings that
Treg cell proliferation depends on glycolysis [105].
3.2.4. Memory T cells
After an active infection, T cells undergo contraction and a small
population survives to become memory T cells [3]. Memory T cells are
long-lived cells that can quickly expand to large numbers of effector T
cells upon re-exposure to their cognate antigen [3]. During memory T
cell development glycolysis is reduced, while mitochondrial
metabolism fueled by fatty acid oxidation is enhanced [109,110] (see
Fig. 1). This may be an important adaptation for memory cells, since
enhanced mitochondrial metabolism may be necessary for expediting
responses of memory T cells upon restimulation with the cognate an-
tigen [109]. To increase fatty acid oxidation, memory T cells increase
the expression of the enzyme carnitine palmitoyl transferase 1, which is
a rate limiting enzyme in fatty acid oxidation [110]). The importance of
the increase of this enzyme is shown by the fact that inhibition of the
enzyme reduced fatty acid oxidation and oxidative phosphorylation
[110]. This specific mitochondrial metabolism in memory T cells is
associated with distinct changes in mitochondrial morphology [22].
Memory T cells have a more fused network of mitochondria, which is
associated with improved oxidative phosphorylation, while effector T
cells have more isolated mitochondria [22]. These mitochondrial
changes are mediated by enhance expression of dynamin-related pro-
tein 1 and OPA1 [22].
In memory T cells, mTOR is less important since the central function
of mTOR is induction of cellular growth and proliferation. In memory T
cells, another protein kinase is important, adenosine monophosphate-
activated kinase (AMPK). This is, like mTOR, an intracellular nutrient
sensor, but it increases fatty acid oxidation and oxidative phosphor-
ylation [111]. mTOR may negatively regulate memory T cell develop-
ment, since inhibiting mTOR increases antigen specific CD8 memory T
cells in mice with lymphocyte choriomeningitis infection and in pri-
mates vaccinated against vaccinia virus [112].
4. Mitochondrial DAMPs
The sections above describe the importance of mitochondria and
mitochondrial metabolism in immune cell functioning. Mitochondria,
being of bacterial origin and still sharing several features with bacteria
[1], also release DAMPs that just like bacterial derived PAMPS, may
activate and sustain immune responses. Such DAMPs arise for instance
from the mitochondrial membrane in which specific phospholipids are
present that are unique to mitochondria and prokaryotes and are not
Fig. 2. Effects of mitochondrial DAMPs on immune responses.
Various mitochondrial DAMPs can be released into the cell cytosol or into the extracellular space and circulation. Mitochondrial proteins may bind to FRP receptors
inducing the production of chemoattractants. Mitochondrial ROS are important for intracellular signaling, although excess ROS production may damage cells.
Mitochondrial ATP and cardiolipin may activate the NLRP3 inflammasome or TLR4 and induce the production of pro-inflammatory cytokines. Mitochondrial DNA
may activate TLR9, NLRP3 inflammasomes or the cGAS pathway resulting in production of pro-inflammatory cytokines.
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found in eukaryotes [113]. One such lipid, prominently present in the
inner mitochondrial membrane is cardiolipin [114]. Moreover, mi-
tochondria have their own DNA, which is circular with hypomethylated
CpG motifs, while mitochondrial proteins have a formylated methio-
nine at the N-terminus, which is specific for mitochondria and bacteria
[115,116] (see Fig. 2). These mitochondrial products may act as DAMPs
when released into the cytosol or extracellular space and circulation.
4.1. Innate immune recognition of DAMPs
Innate immune cells, but also adaptive immune cells [117], have
various Pattern Recognition receptors (PPRs) to detect PAMPs and
DAMPs. The most well-known PPR are Toll-like receptors (TLR). TLR
are membrane bound or intracellular receptors, expressed by all innate
immune cells, which detect DAMPs or PAMPs [118]. TLR4 for instance
detects lipopolysaccharide (LPS) a membrane component of gram-ne-
gative bacteria; TLR2 detects cell wall components such as lipopeptides
and peptidoglycan, from gram-positive bacteria. TLR9, detects un-
methylated CpG DNA motifs [119].
Cardiolipin is a phospholipid present in the inner mitochondrial
membrane [114]. Cardiolipin is highly enriched in linoleic acids, with
double bonds and therefore is susceptible to oxidation [120]. In healthy
individuals, cardiolipin is not oxidized [121]. During disease, cardio-
lipin may become oxidized after which it promotes its own release from
mitochondria and can be found in the circulation [122,123]. Oxidized
cardiolipin is a TLR4 agonist and promotes pro-inflammatory cytokine
production, production of leukotrienes in macrophages and it also in-
duces activation of endothelial cells [122,123]. Also, mitochondrial
DNA can stimulate TLRs. Mitochondrial DNA contains hypomethylated
CpG motifs, which are recognized by TLR 9 in the endolysosomal
compartment of the cell [124]. The signaling pathway of TLR9 results
in activation of Mitogen-activated Protein Kinases (MAPK) and NF-kB
to trigger pro-inflammatory cytokine production and inflammatory re-
sponses [125]. In various inflammatory diseases, it has now been shown
that mitochondrial DNA is increased in the circulation [126]. Mi-
tochondrial proteins have formylated methionine at the N-terminus,
which are recognized by Formyl Peptide receptors (FPR). Binding of
these peptides to FPR results in production of chemoattractants, and
therefore recruitment of immune cells to the site of infection [127].
Another route by which mitochondrial DAMPS can contribute to
immune responses is by activating inflammasomes, mainly the NLRP3
inflammasomes. Inflammasomes are cytoplasmic protein complexes,
consisting of receptor and sensor molecules, an adaptor protein and
caspase 1 [128]. The NLRP3 inflammasome, containing the NOD-, LRR-
and pyrin domain-containing protein 3 (NLRP3) is activated by a wide
range of mitochondrial ligands, such a ATP, mitochondrial DNA, mi-
tochondrial ROS but also by mitochondrial dysfunction and cardiolipin
[128]. Upon activation of NLRP3, caspase-1 is recruited to the in-
flammasome by an adaptor protein apoptosis-associated speck-like
protein, which contains a caspase recruitment domain [128]. Upon
activation of caspase-1, it cleaves pro-interleukin-1β and pro-inter-
leukin 18 to their biological forms [128].
Mitochondrial DNA could also affect immune responses by the cGAS
(cyclic AMP-GMP synthase) pathway [129]. The cGAS pathway is part
of the innate immune system that detects the presence of DNA in the
cytosol and in response triggers type I interferon inflammatory re-
sponses [129]. cGAS and its second messenger cyclic GMP-AMP
(cGAMP) and the sensor of cGAMP, stimulator of interferon genes
(STING) is a major sensing pathway for cytosolic DNA [130]. Stimu-
lation of this pathway by viral DNA leads to induction of type I inter-
ferons, which prevents viral replication, assembly and release, and NF-
kB activation and induction of proinflammatory cytokines [130,131].
NF-kB controls the transcription of proinflammatory cytokines and
chemokines [132]. The cGAS-STING pathway is linked to autophagy
pathways and cell-death pathways [133–136]. Also mitochondrial DNA
can activate the cGAS-STING pathway [137–139].
4.2. Mitochondrial DAMPs and inflammation
Since circulating mitochondrial DNA is increased in various infec-
tions, mitochondrial DAMPS are suggested to be an important me-
chanism in detection of an infection and stimulating and maintaining
immune responses against pathogens [140,141]. However, on the other
hand, the sensing of mitochondrial DAMPs may also stimulate un-
desired immune responses in case of traumatic tissue damage and may
result in unwanted inflammation. To prevent undesired inflammation
under physiological conditions, cells have various mechanisms to sca-
venge the DAMPs during cell damage. One of these mechanisms is
mitophagy. Mitophagy is the process of autophagy of mitochondria
[142]. During mitophagy, damaged mitochondria are taken up by the
autophagosome and the mitochondrial DNA is degraded by DNase II
nuclease activity [143,144]. Another mechanism is to prevent leakage
of mitochondrial products into the cell. To do so, mitochondrial
membrane permeabilization is tightly regulated. The outer mitochon-
drial membrane is permeable for metabolites involved in oxidative
phosphorylation [145]. The inner mitochondrial membrane is im-
permeable [146]. Various specific transporters and exchangers exist to
transport molecules over the inner mitochondrial membrane [146]. In
certain physiological and pathophysiological conditions, mitochondrial
membrane permeability may change. In mitochondrial permeability
transition, the mitochondrial inner membrane becomes permeable,
leading to mitochondrial depolarization, failure of oxidative phos-
phorylation and as a consequence mitochondrial swelling and cell death
is induced [147,148]. Another mechanism protecting cells from un-
desired immune activation by mitochondria is that in situations of in-
creased mitochondrial membrane permeabilization, caspase-9 depen-
dent mechanisms are triggered to silence the cGAS pathway [137].
In conditions of massive cell damage, such as during traumatic in-
jury or cardiac disease, the protective mitochondrial mechanisms may
not be working or may be overwhelmed and mitochondrial DAMPs may
be released into the cytosol and the circulation [149]. This may trigger
an unwanted pro-inflammatory response. Even in the absence of an
infection, such a pro-inflammatory response may be as severe as seen
during septic shock in uncontrolled infections. The role of mitochondria
in such a sterile inflammation is illustrated in studies demonstrating
increased levels of mitochondrial DNA in the circulation of patients
with major trauma (without infection) [150,151]. Also in a mouse
model of pressure overload, which is not associated with infections, it
has been demonstrated that mitochondrial DNA is increased leading to
inflammation and damage of heart muscle cells, thereby inducing ab-
normalities in cardiac structure and function and finally inducing heart
failure [144]. Also, injecting exogenous mitochondrial extracts into
experimental animals induced an inflammatory response like in septic
shock [151].
5. Mitochondrial dysfunction in immune cells in immunological
diseases
5.1. Systemic lupus erythematosus (SLE)
SLE is a systemic autoimmune disease, which is characterized by the
production of pathogenic autoantibodies by immune cells, inducing
injuries in multiple organs [152]. Various studies have recently shown
that mitochondrial dysfunction in immune cells may play a role in the
pathogenesis of SLE. SLE is characterized by abnormal T cell activation,
with overproduction of ROS in the mitochondria of these cells
[153,154]. This, together with a decreased antioxidant capacity
[154,155], may explain the higher levels of ROS in plasma and urine of
SLE patients [154,155]. Since increased oxidative stress may arise from
increased ROS production due to mitochondrial dysfunction, various
groups have now studied mitochondrial function in immune cells in
SLE. Mitochondria in T cells of SLE patients have a high mitochondrial
membrane potential and decreased ATP production, indicating
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mitochondrial damage [156]. Peripheral blood mononuclear cells
(PBMC) from SLE patients show low basal mitochondrial oxygen con-
sumption rates [157]. Lee et al. showed a decrease in glycolytic en-
zymes and mitochondrial related proteins in leukocytes of SLE patients
[155], while Wahl et al. showed that mitochondria of T cells of SLE
patients only showed decreased glycolysis [158] but not impaired mi-
tochondrial respiration. These contradicting observations show dis-
turbances in mitochondrial metabolism in immune cells in SLE, but at
the same time indicate that further research is necessary into mi-
tochondrial function in immune cells in SLE. A role for mitochondria in
T cells of SLE patients can also be observed from the findings that
mTOR is activated in T cells in SLE patients [159]. Inhibition of the
mTOR by rapamycin in lupus prone mice inhibits SLE [160,161].
Moreover, promising effects of a clinical trial of rapamycin treatment in
patients with active SLE have been shown [162]. Recently, Lee et al.
showed that in SLE mitochondrial dysfunction was associated with
oxidative damage and cytokine production [163] and suggested that
mitochondrial dysfunction is implicated in the pathophysiology of SLE.
The available evidence so far thus suggests that mitochondrial dys-
function in immune cells in SLE may play a role in the pathogenesis of
SLE.
5.2. Rheumatoid arthritis
Rheumatoid arthritis (RA) is an autoimmune disease characterized
by chronic inflammation of the synovium [164]. Various types of au-
toantibodies, which play an important role in the induction of the
disease, can be found in the plasma of RA patients [164]. Mitochondrial
DNA has also been found to be increased in the plasma of RA patients.
This mitochondrial DNA may act as a DAMP and induce or maintain
inflammatory responses in RA [165]. T cells play an important role in
the production of antibodies by B cells [3] and CD4 positive naïve T
cells from patients with RA show various defects, amongst which mi-
tochondrial dysfunction: mitochondria in T cells in RA have defective
DNA repair mechanisms, which is associated with low mitochondrial
oxygen consumption and ATP production [166]. Activated T cells in RA
suppress glycolysis [167] but enhance the activity of the Pentose
Phosphate Pathway [168]. Decreased glycolysis and low pyruvate
production will slow down the TCA cycle, resulting in transportation of
citrate into the cytoplasm, where it is used to synthesize fatty acids
[169]. Also, the decreased beta-oxidation in mitochondria of RA in T
cells, results in fatty acids accumulation in the cytoplasm [170]. Indeed,
it has been shown that T cells in RA patients have upregulated lipo-
genesis [170]. These fatty acids are stored in lipid droplets in the cell
and can be used for building new cells and for T cell invasion ma-
chinery, enabling proliferation and invasion of T cells into the syno-
vium [171].
5.3. Diabetes
Type 1 diabetes is an autoimmune disease in which beta cells in the
pancreas are destroyed by an autoimmune process [172]. Im-
munologically, Type 1 diabetes is characterized by a Th1 type immune
response involving adaptive and innate immune cells [173]. Also, in
type 1 diabetes, mitochondrial dysfunction has been shown, such as
mitochondrial membrane hyperpolarization in T cells [174]. This mi-
tochondrial membrane hyperpolarization is associated with increased
mitochondrial ROS production and increased IFNɣ production in T
helper cells and with increased cytotoxicity in cytotoxic T cells in dia-
betes type 1 [174]. Moreover, T cells isolated from type 1 diabetic
patients show decreased ATP production, also indicating mitochondrial
dysfunction [174]. Since this mitochondrial dysfunction was only ob-
served in type 1 diabetes and not in type 2 diabetes [174], it is assumed
that mitochondrial dysfunction in type 1 diabetes does not result from
metabolic abnormalities and that this mitochondrial dysfunction may
play a role on the pathogenesis of type 1 diabetes.
Although in type 2 diabetes mitochondrial dysfunction was not
observed in T cells, increased levels of circulating mitochondrial DNA
were observed in type 2 diabetes patients [175]. This suggests that this
mitochondrial DNA does not arise from T cells but from other sources.
Since mitochondrial DNA may activate TLR9, thereby activating in-
flammatory cells, this mitochondrial DNA could be involved in acti-
vating and maintaining the inflammatory responses characterizing type
2 diabetes [176].
5.4. Pregnancy
In order to accept the semi-allogeneic fetus, pregnancy is associated
with various changes in the immune response, such as a shift away from
a Th1 immune response towards a Th2 immune response [177–180],
increased numbers of Treg cells and decreased numbers of Th17 cells
[181,182]. Moreover, there is a generalized mild activation of the in-
flammatory response [183,184]. Various factors are suggested to be
involved in inducing these immunological changes during pregnancy,
such as hormonal changes [185], factors produced by the placenta
[186–188] and pertinent changes in the gut microbiome favoring a
tolerogenic immune response [189]. In view of the recent knowledge on
the role of mitochondria in immune cell function, we would expect
changes in mitochondrial function in immune cells during pregnancy.
However, to the best of our knowledge, there are no data on mi-
tochondrial (dys) function in immune cells during pregnancy. Recently,
however, it was shown that circulating mitochondrial DNA was in-
creased during pregnancy [190]. This paper measured absolute mi-
tochondrial DNA and contradicted another study which found de-
creased mitochondrial DNA in plasma during pregnancy [191]. In this
latter study, however, mitochondrial DNA was normalized to nuclear
DNA and the correlation between mitochondrial DNA and nuclear DNA
may vary during pregnancy [190]. The question arises whether, next to
all other mechanisms known to affect the maternal immune response,
also circulating mitochondrial DNA, is involved as DAMP in inducing
the immunological changes during pregnancy. Further research is ne-
cessary to be able to answer this question.
Various pregnancy complications are associated with im-
munological changes, such as preeclampsia [192] and gestational dia-
betes mellitus [193], which are the main pregnancy complications.
Unfortunately, nothing is known about differences in mitochondrial
function in immune cells between healthy pregnancy and preeclampsia.
Gestational diabetes mellitus which is defined as glucose intolerance
developing during pregnancy [194], is characterized by generalized
inflammation in the maternal circulation [193,195]. Recently Qu et al.
showed that mitochondrial function in monocytes was reduced in ge-
stational diabetes mellitus, resulting in increased oxidative stress [196].
They showed higher mitochondrial superoxide and ROS production, as
well as a decreased mitochondrial membrane potential [196]. Also, in
gestational diabetes mellitus the role of mitochondria in immune cell
function needs to be further explored.
In preeclampsia, mitochondrial DNA has been shown to be further
increased as compared with healthy pregnancy [197–199] and may
activate TLR9 on immune cells [200]. This mitochondrial DNA was
suggested to play a role in the pathogenesis of preeclampsia, since it
was already increased in early pregnancy before the onset of pre-
eclampsia [199,201]. Further research is necessary to implicate a role
for mitochondrial DNA in the pathogenesis of preeclampsia, but also to
identify the source of mitochondrial DNA. It may be speculated that the
placenta is the source of the increased circulating mitochondrial DNA
during preeclampsia, since mitochondrial dysfunction has been shown
in the placenta of women with preeclampsia [202].
6. Conclusions
It is clear from currently available literature that there is a link
between immune cell activation and immune cell metabolism. It is now
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generally accepted that increased glycolysis is mostly associated with a
pro-inflammatory phenotype in immune cells (such as in monocytes
and M1 macrophages), while oxidative phosphorylation and fatty acid
oxidation is more associated with a regulatory phenotype and induction
of long-living immune cells (such as in Treg cells, M2 macrophages and
memory T cells). Although our knowledge on immunometabolism is
increasing, there is still little knowledge on the role of mitochondrial
function in immunological diseases. We are starting to unravel mi-
tochondrial dysfunctions in various autoimmune diseases, such as RA,
SLE and diabetes, however, the causal relationship between mi-
tochondrial dysfunction and disease induction or maintenance is still
unclear. Also, the role of mitochondrial function during pregnancy and
its complications is unclear currently.
Further unraveling of the role of mitochondrial dysfunction in au-
toimmune diseases, especially studying mitochondrial function in the
various subtypes of immune cells in these diseases, may lead to new
treatment options based on improving mitochondrial function in one or
more immune cell subsets. Focus should not only be on the mitochon-
dria itself, but also on the mTOR pathway and other pathways that
affect mitochondrial function and which could be inhibited or activated
in order to stimulate or inhibit certain immune cells. Little is known
about these pathways in immune cells of patients with autoimmune
diseases. Some examples show promising effects of therapeutic ap-
proaches affecting the mTOR pathway: inhibition of mTOR may en-
hance vaccination efficiency [112] and may also have beneficial effects
on immune senescence in elderly people [203]. Moreover, promising
effects of a clinical trial of rapamycin treatment in patients with active
SLE have been shown [162]. Further insight into role of mitochondria
and mTOR and its downstream pathways could lead to more persona-
lized medicine, based on improving mitochondrial function in one or
more immune cell subsets in different patients' groups.
Future studies should not only focus on mitochondrial function in
immune cells in immunological/inflammatory diseases, it is also im-
portant to focus further on the role of mitochondrial DAMPs in im-
munological/inflammatory diseases. Such mitochondrial DAMPs have a
specific structure and have been shown to reach high levels during
severe undesired inflammatory events such as during traumatic injury
or cardiac disease. Further insight into the role of mitochondrial
DAMPS in various diseases, but also during pregnancy, might provide
new personalized management strategies to control these disorders by
inhibition of release of mitochondrial DAMPs or neutralizing these
DAMPs.
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